Please assess the completion status of the following clinical trial:

Trial Title: 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who had received a primary or secondary kidney transplant~* Patients who were willing and from whom written informed consent was obtained~* kidney allograft with a cold ischemia time (CIT) \< 30 hours~* negative pregnancy test prior to study enrollment~Exclusion Criteria:~--Multi-organ recipients~* former Graft loss due to immunological reasons~* Patients who received a kidney from a non-heart beating donor~* A-B-0 incompatible transplants~* a current Panel Reactive Antibody (PRA) level of \> 20%~* existing antibodies against the HLA-type of the receiving transplant~* a known hypersensitivity/contraindication to any of the immunosuppressants~* Use of other investigational drugs~* Patients with thrombocytopenia (platelets \< 100,000/mm³), with an absolute neutrophil count of \< 2,000/mm³ or leucopenia (leucocytes \< 3,000/mm³), or hemoglobin \< 8 g/dL~* significant mental illness~* history of malignancy during the last five years~* HIV positive~* uncontrolled hypercholesterolemia or hypertriglyceridemia~* drug or alcohol abuse~* pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAC+MPA (Type: ACTIVE_COMPARATOR): None
- TAC+Certican (Type: EXPERIMENTAL): None
- CycA+Certican (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).